DrugPatentWatch Database Preview
TECHNIVIE Drug Profile
When do Technivie patents expire, and when can generic versions of Technivie launch?
Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has four hundred and fourteen patent family members in forty-seven countries.
The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
Summary for TECHNIVIE
| International Patents: | 414 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TECHNIVIE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TECHNIVIE |
| DailyMed Link: | TECHNIVIE at DailyMed |
Generic Entry Opportunity Date for TECHNIVIE
Generic Entry Date for TECHNIVIE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TECHNIVIE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 3 |
Recent Litigation for TECHNIVIE
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| AbbVie Inc. v. Cipla Limited | 2017-11-10 |
| AbbVie Inc. v. Aurobindo Pharma Limited | 2017-01-13 |
| AbbVie Inc. v. Amneal Pharmaceuticals, LLC | 2016-05-27 |
Synonyms for TECHNIVIE
| Ombitasvir / paritaprevir / ritonavir |
| Ombitasvir and paritaprevir and ritonavir |
| Ombitasvir mixture with paritaprevir and ritonavir |
| S900007110 |
US Patents and Regulatory Information for TECHNIVIE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TECHNIVIE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TECHNIVIE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Peru | 00382014 | Start Trial |
| Spain | 2546767 | Start Trial |
| Taiwan | 201417826 | Start Trial |
| Uruguay | 32699 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2012083170 | Start Trial |
| European Patent Office | 2853531 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TECHNIVIE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2692346 | 299 50017-2017 | Slovakia | Start Trial | PRODUCT NAME: PIBRENTASVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
| 2368890 | 92668 | Luxembourg | Start Trial | PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119 |
| 2692346 | 51/2017 | Austria | Start Trial | PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 (MITTEILUNG) 20170728 |
| 2340029 | C20150019 00156 | Estonia | Start Trial | PRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015 |
| 2340029 | 122015000042 | Germany | Start Trial | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115 |
| 2340029 | 300730 | Netherlands | Start Trial | PRODUCT NAME: PARITAPREVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
